AbbVie announced the start of construction on a $70 million expansion at its AbbVie Bioresearch Center (ABC) in Worcester, Massachusetts. The site serves as a center of excellence for biologics research, development, and manufacturing.

This initiative reflects AbbVie’s long-term commitment to advancing scientific innovation in the U.S. and is part of the company’s previously announced pledge to invest more than $10 billion in domestic capital projects to support innovation and expand biologics manufacturing capacity.

The expansion will significantly enhance AbbVie’s ability to meet growing global demand for biologics, particularly in oncology and immunology. Plans include new biologics manufacturing areas and a three-story facility that will house laboratories, warehouse space, and offices. Once complete, the project will also enable the transfer of select oncology products from Europe to the U.S., further strengthening AbbVie’s domestic production capabilities.

“For more than three decades, the AbbVie Bioresearch Center has been at the forefront of biologics innovation and manufacturing,” said Azita Saleki-Gerhardt, Ph.D., executive vice president and chief operations officer, AbbVie. “This expansion will position ABC to build on its strong track record of developing and launching complex biologic medicines that improve the lives of millions of patients worldwide.”

AbbVie employs approximately 28,000 people across all 50 states and Puerto Rico, including more than 2,000 employees in Massachusetts. The Worcester expansion is expected to create new jobs at the ABC site while adding advanced capabilities to AbbVie’s U.S. manufacturing footprint, which already supports more than 6,000 jobs across 11 sites nationwide.